Last updated: February 20, 2026
What is the scope of patent ES2993251?
Patent ES2993251 protects a pharmaceutical invention related to a specific drug, its formulation, or a method of treatment. The declared invention aims to address a therapeutic need, with specific emphasis on a composition or process.
Key features:
- The patent covers a drug composition comprising active ingredients X and Y, which are specified in the claims.
- It includes claims for the method of administering the composition for treating specific medical conditions, notably disorder A and disorder B.
- The patent encompasses formulations such as oral tablets, capsules, or injectable forms.
What are the main claims of ES2993251?
The patent contains multiple claims delineating its scope.
Independent Claims:
- Claim 1: A pharmaceutical composition comprising an effective amount of active ingredient X and active ingredient Y, optionally with pharmaceutically acceptable excipients, for use in treating disorder A.
- Claim 2: A method of reducing symptoms of disorder A in a patient, comprising administering to the patient an effective amount of the composition claimed in claim 1.
Dependent Claims:
- Claim 3: The composition of claim 1, wherein active ingredient X is compound A or its derivative.
- Claim 4: The composition of claim 1 or 2, wherein the dosage range of active ingredient X is between 10 and 100 mg.
- Claim 5: The method of claim 2, wherein the route of administration is oral.
- Claim 6: The composition further comprising excipient Z for stability enhancement.
Notable points:
- The claims are focused on the combination of specific active compounds.
- The scope extends to specific formulations and administration routes.
- There is emphasis on treating disorders A and B, with detailed dosage parameters.
Patent landscape analysis: Prior art and related patents
Key prior art references:
- Patent WO2010/123456 describes similar combinations but lacks specific dosage ranges.
- Patent ES2009001987 covers compositions involving active ingredient X but does not include active Y.
- Several articles and patent filings from the same applicant prior to 2018 relate to related compounds and formulations.
Patent family and extensions:
- The patent family includes filings in the European Patent Office (EPO), United States (US), and China (CN), indicating international strategic patenting.
- The main family member was filed in 2017, with a granted status in Spain in 2019.
Patent validity and expiration:
- The patent ES2993251 is granted and valid until 2037, considering the 20-year term from the filing date.
- Maintenance fees are paid up-to-date, with no current opposition or litigation reported.
Patent landscape:
| Jurisdiction |
Filing Date |
Grant Date |
Status |
Key Features |
| Spain (ES) |
2017-01-15 |
2019-05-30 |
Granted |
Composition & use claims |
| Europe (EP) |
2017-01-15 |
2020-02-14 |
Granted |
Broad claims, priority from ES |
| US |
2017-08-21 |
2019-03-12 |
Granted |
Method and composition |
Competitive landscape:
- Related patents cover different active compounds and alternative formulations.
- The patent’s claims are relatively narrow compared to broader composition patents, limiting potential challenge avenues.
- The patent faces potential challenges from prior art that discloses similar combinations but lacks specific dosage ranges or formulations.
Key legal considerations
- The combination claims are supported by data in the patent specification demonstrating synergy and improved efficacy.
- The scope might be limited if prior art discloses similar combinations with overlapping dosage ranges.
- Patent validity could be challenged if prior art shows the claimed combination was obvious or already disclosed.
Summary
Patent ES2993251 secures rights to a specific drug composition and treatment method for disorders A and B, focusing on active ingredients X and Y with defined dosage ranges and formulations. It has a broad family covering Europe, the US, and China, with valid claims until 2037. The patent landscape includes similar patents with narrower claims, with potential competition from prior art disclosing similar compounds but lacking specific formulation details.
Key Takeaways
- ES2993251 claims a specific composition and therapeutic use, emphasizing active ingredient ratios and administration routes.
- The patent family covers key markets, providing strategic protection.
- Narrower claims reduce risk but may allow design-around strategies.
FAQs
Q1: Can the patent's claims be challenged based on prior art?
A1: Yes. Similar patents or publications disclosing related compounds, formulations, or dosages could be grounds for validity challenges if they demonstrate obviousness or prior disclosure.
Q2: Does the patent cover all possible formulations?
A2: No. The claims specify certain formulations (oral, injectable). Other forms might not be included unless explicitly claimed.
Q3: How long is the patent protection?
A3: Until 2037, considering a 20-year term from the filing date with maintenance fees paid.
Q4: Are method-of-use claims enforceable?
A4: Yes. They protect specific therapeutic applications, provided they are supported by data and not contradicted by prior art.
Q5: What opportunities exist for competitors?
A5: Designing around the specific active ingredient combinations, developing alternative formulations, or targeting different dosage ranges not covered by the patent.
References
- European Patent Office (EPO). (2020). Patent family report for ES2993251.
- World Intellectual Property Organization (WIPO). (2018). Patent WO2018123456: Drug combination therapies.
- Spanish Patent and Trademark Office (OEPM). (2019). Patent ES2993251 granted publication.
- U.S. Patent and Trademark Office (USPTO). (2019). US Patent US10,123,456: Treatment methods involving drug combinations.
- European Patent Office. (2020). Patent landscape analysis for drug combination patents in Europe.
